Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAYONET: Encorafenib + binimetinib + cetuximab after encorafenib + cetuximab failure in BRAF V600E-mutant metastatic colorectal cancer
jRCTs031210510Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib, binimetinib and cetuximab in colorectal cancer (CRC), sponsored by Ono Pharmaceutical. Primary endpoint: Progression-free survival rate at 12 weeks. Started Feb 2022; status: completed.
02
Drugs
encorafenibbinimetinibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031210510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210510.